Daewoong finishes resubmitting documents for Nabota to FDA

Published: 2018-08-07 16:29:00
Updated: 2018-08-07 16:15:21

Daewoong Pharmaceutical’s botulinum toxin ‘Nabota’ has taken the last step to enter the U.S. market.

Daewoong Pharmaceutical(CEO Seung-Ho Jeon) announced on the 2nd that they turned in revised documents to the U.S. FDA and resumed the application process for Nabota’s sales approval in the U.S. T...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.